Adjuvant solution for pandemic influenza vaccine production - Wikidata - wikimedia - TriplyDB

Adjuvant solution for pandemic influenza vaccine production

Adjuvant solution for pandemic influenza vaccine production

http://www.wikidata.org/entity/Q30422038

about

Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants A Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple Formulations Novel Anti-Nicotine Vaccine Using a Trimeric Coiled-Coil Hapten Carrier Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses Clinical vaccine development for H5N1 influenza.Adjuvants and immunization strategies to induce influenza virus hemagglutinin stalk antibodies GLA-AF, an emulsion-free vaccine adjuvant for pandemic influenza.Comparison of a novel microcrystalline tyrosine adjuvant with aluminium hydroxide for enhancing vaccination against seasonal influenza.A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines.Memory CD4 T cell-mediated immunity against influenza A virus: more than a little helpful.Construction of an enantiopure bivalent nicotine vaccine using synthetic peptides.IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice.Vaccine self-assembling immune matrix is a new delivery platform that enhances immune responses to recombinant HBsAg in mice Avian influenza A(H5N1) and A(H9N2) seroprevalence and risk factors for infection among Egyptians: a prospective, controlled seroepidemiological study Schistosome Vaccine Adjuvants in Preclinical and Clinical Research.Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens Protection and Long-Lived Immunity Induced by the ID93/GLA-SE Vaccine Candidate against a Clinical Mycobacterium tuberculosis Isolate.Avian Influenza A(H5N1) Virus in Egypt Intranasal immunization with influenza antigens conjugated with cholera toxin subunit B stimulates broad spectrum immunity against influenza viruses.Selection of therapeutic H5N1 monoclonal antibodies following IgVH repertoire analysis in mice.MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant Toll-like receptor 7 agonist imiquimod in combination with influenza vaccine expedites and augments humoral immune responses against influenza A(H1N1)pdm09 virus infection in BALB/c mice.Vaccine design: emerging concepts and renewed optimism.Immunologic correlates of protection and potential role for adjuvants to improve influenza vaccines in older adults.Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.IL-18 and Subcapsular Lymph Node Macrophages are Essential for Enhanced B Cell Responses with TLR4 Agonist Adjuvants.Effect of Immunosuppression on T-Helper 2 and B-Cell Responses to Influenza Vaccination.The use of self-adjuvanting nanofiber vaccines to elicit high-affinity B cell responses to peptide antigens without inflammation.Pyriproxyfen enhances the immunoglobulin G immune response in mice.From empiricism to rational design: a personal perspective of the evolution of vaccine development.Improved Immune Responses in Young and Aged Mice with Adjuvanted Vaccines against H1N1 Influenza Infection.Unlocking pandemic potential: prevalence and spatial patterns of key substitutions in avian influenza H5N1 in Egyptian isolates.Avian Influenza A Virus Infection among Workers at Live Poultry Markets, China, 2013-2016.αv Integrins regulate germinal center B cell responses through noncanonical autophagy

P2860

Q27025822-DCEDCB99-E258-4802-AFAE-0E9E842F567A Q27321020-45809218-FD6F-47F7-A1DD-87100FE3EB64 Q28542642-65781FD7-4A70-4767-9712-2E54397B50BB Q30205195-C2C28638-913E-43A0-BA7D-2FB33161E752 Q30222083-C2DF070E-F5BD-4239-8244-ACF749935BFE Q30355516-A389FAC4-0233-497A-8EB6-CFFC9338DA6B Q30359243-1AA9EFB5-FE42-422F-A175-BF93B8F3C9F1 Q30400393-75E7E73E-A201-41A7-A224-1D56EE3E2C86 Q30401247-633EA7EC-7846-4221-8CF1-4035C6160836 Q30431078-BACFBAFE-374C-4B61-8DBA-4C3C07098EB4 Q33751968-51DC7C92-F86F-40FF-9CF2-C92071D3FB08 Q34400813-F411895D-B883-47AD-9A1F-3D2E7ABD35B2 Q35122785-2D8014B4-0ACA-4998-B449-5FAD343F6B8D Q35715601-C918CD2D-AD9E-4558-BF31-08F853A52EFC Q35826651-70425F11-D8FC-43B7-8A62-4050331FD732 Q36500269-5528D123-BD2C-4A90-B9BC-EFF9917CEF2F Q36555077-B76F172F-4A54-436B-BC8F-70E91B3D31BC Q36617093-F04304FA-9938-48F8-A585-9F880EA7986A Q36977642-5BA87594-A6B3-413E-B108-EEE00EF40D97 Q37069543-6D0DD506-5378-48EC-8686-AE9F880984AD Q37243896-2C37FA4D-13D7-4256-AC79-81109582B6BC Q37712843-0FA2AAB2-E2CE-4236-B110-0DAE7BEA1826 Q38087785-A2E5DE7E-662A-420E-A1C8-5055E75C2CA2 Q38124061-57032D39-B692-468F-85B7-E69CC7781798 Q40116011-360A6656-388D-4671-A13C-7242A212FEFD Q40476014-EF3E96D0-14DD-43A1-8620-82FC0AE90500 Q41544620-7DB3D3F3-D7FB-4A5A-B053-FD94AAA5BEC2 Q42926219-D6DAD864-3E82-41E1-B83B-5070560947E1 Q45072385-1A0F7E3F-8998-4710-9A01-5D98A4E7DCD8 Q47633699-126A75A5-3D04-45EE-92DB-9F9CFE7CD4AD Q51743232-9EAC4A7D-E0F9-4D64-B900-5BBD23E2B5FE Q55491209-4FCBC89C-EA82-41AE-8559-BEBAEE016040 Q55615400-6B42C6A7-0D39-4CE8-9782-3EDD9066602D Q56944872-76F4DE8E-ABAF-4FDF-8BEC-F10EF4E4DAC2

P2860

Adjuvant solution for pandemic influenza vaccine production

http://www.wikidata.org/entity/Q30422038

description

2012 nî lūn-bûn

@nan

2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Adjuvant solution for pandemic influenza vaccine production

@ast

Adjuvant solution for pandemic influenza vaccine production

@en

type

label

Adjuvant solution for pandemic influenza vaccine production

@ast

Adjuvant solution for pandemic influenza vaccine production

@en

prefLabel

Adjuvant solution for pandemic influenza vaccine production

@ast

Adjuvant solution for pandemic influenza vaccine production

@en

P1433

Q30422038-A2525806-1F31-4076-94B4-0E5959B8F974

P1476

Q30422038-DEF96839-1F44-42AD-A7F5-4BAA6CFCE34C

P2093

Q30422038-7CEE437A-A690-4545-9FAA-D2BCEFA17A71

Q30422038-A249BB76-A3D4-41BD-82ED-0D0EF54506F1

Q30422038-BFEB95D5-537E-4743-B23B-1984C039CBCA

Q30422038-DC6CDE15-B583-4EE3-804D-3A21E95BAC2E

Q30422038-E8AEEE99-5897-47AB-ADB1-A243A4BCA318

P2860

Q30422038-0148B4C7-1019-45AC-8B1D-8964EC64EF61

Q30422038-12EBEFB5-7D6D-451F-B5E9-3C0B4D69E921

Q30422038-16FBF65A-200C-43C2-97C4-9885F8908C62

Q30422038-2DA73244-CAC5-453B-A619-CB62CF541B90

Q30422038-362A83E9-3D1C-4517-9708-3208CBF99856

Q30422038-370C5968-3567-4C76-8737-7FEC00EBD70E

Q30422038-3EB8739C-359F-416E-BD94-B7E668DBDBFB

Q30422038-5C3A7365-629F-4552-BE6B-86C59377D72D

Q30422038-60D3601C-55A7-4A52-98C6-ABC65976903F

Q30422038-617C1D24-BB61-4511-81A1-6F9CEB9D84EF

P304

Q30422038-D02AD6EE-7771-4C1E-A50F-B62DCFFBFD75

P31

Q30422038-A92EC9D8-261C-437D-917D-605936DDBC7C

P356

Q30422038-AFB935CF-F7B1-47A4-BFB2-7FE864B10937

P407

Q30422038-973E2636-564E-48A7-B705-9BDA1D0B382D

P433

Q30422038-2B311974-678C-4BF7-9E54-16A66A48B8F0

P478

Q30422038-861AEF0B-D5F7-4FED-948B-D984E2004D63

P50

Q30422038-2E933B95-8C59-463D-9BA3-19E4FD2B6EA8

Q30422038-30EE9FEA-9286-465F-8573-04C1726AAF5A

Q30422038-DECE5CB0-B764-45FB-8C1C-F9C968D8525C

P577

Q30422038-9C5C8E19-492A-4E60-8429-852C148840C4

P5875

Q30422038-459CC840-9050-4122-9559-049BC122AFA6

P698

Q30422038-6E40B6A3-393C-40B7-BF75-B0AEC3473B0A

P921

Q30422038-FFA9D739-2B6C-44CF-A7F7-01237D0DC6CE

P932

Q30422038-CB689726-DA49-455C-A870-B57E94E455FD

P356

PNAS.1207308109

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Adjuvant solution for pandemic influenza vaccine production

@en

P2093

Christopher H Clegg

http://www.w3.org/2001/XMLSchema#string

Joseph A Rininger

http://www.w3.org/2001/XMLSchema#string

Neal Van Hoeven

http://www.w3.org/2001/XMLSchema#string

Richard Roque

http://www.w3.org/2001/XMLSchema#string

Susan L Baldwin

http://www.w3.org/2001/XMLSchema#string

P2860

Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant

A synthetic adjuvant to enhance and expand immune responses to influenza vaccines

A fast track influenza virus vaccine produced in insect cells.

Evaluation of vaccines for H5N1 influenza virus in ferrets reveals the potential for protective single-shot immunization

Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans.

Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data.

H5N1 Avian influenza: preventive and therapeutic strategies against a pandemic.

Quantifying the early immune response and adaptive immune response kinetics in mice infected with influenza A virus.

Molecular characterization of in vivo adjuvant activity in ferrets vaccinated against influenza virus

Influenza vaccine immunology.

P304

17585-17590

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1207308109

http://www.w3.org/2001/XMLSchema#string

P407

P433

43

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P50

Richard A Bowen

P577

2012-10-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232223801

http://www.w3.org/2001/XMLSchema#string

P698

23045649

http://www.w3.org/2001/XMLSchema#string

P921

P932

3491477

http://www.w3.org/2001/XMLSchema#string